Pipeline & Partnering Approach

Pipeline & Partnering Approach


PARI maintains multiple partnerships for its inhalation systems under exclusive license agreements in various stages of development and product life cycle.

+ several undisclosed partnerships

Partnering Approach for Inhaled Drugs

Technical feasibility

Collaborations with our partners start in many different ways. In most cases, a technical feasibility study helps to evaluate the compatibility of the specific drug formulation and eFlow® Technology platform. This may include experiments on nebulization and aerosol properties with different configurations of the eFlow Technology platform and different drug formulations. PARI’s Aerosol Services laboratory is equipped and experienced to perform such studies.

Learn more about our Aerosol Services

Support for pre-clinical and clinical development

During pre-clinical and clinical development, PARI supplies nebulizers for the administration of the specific drug product and provides support for regulatory filings (e.g., device sections for IND filing). Dedicated project teams optimize the eFlow® Technology nebulizer to meet the special needs of the target patient population in addition to tailoring the device for use with the specific drug formulation. As part of our services, experts at PARI may provide advice for optimizing certain aspects of the formulation to the eFlow® Technology platform to enable the shortest possible inhalation treatment.

More than 12 companies who develop and commercialize novel inhaled drug products rely on the eFlow Technology platform for their clinical development.


After regulatory approval, PARI supports the launch and commercialization of the drug-device combination by meeting demands for device supply and customer service in worldwide markets as well as by life-cycle management activities for the device.

Committed partnership

Along with development of the product comprised of a specific drug product and an optimized eFlow® Technology nebulizer, the partnership evolves with mutual commitment. PARI grants exclusive rights to the use of the eFlow® Technology platform in specific fields, which can expand/extend the proprietary status of the combination products even beyond the level of the patent protection of drug and device combined.

eFlow Technology nebulizers with digital therapy management: The PARI Connect eco-system

eFlow Technology nebulizers with digital therapy management: The PARI Connect eco-system.

Learn how it supports patients, directly and indirectly, through carefully considered device usability in combination with digital therapy management solutions.​​

Read more

Your innovative aerosol therapy – our drug-nebulizer expertise

Your innovative aerosol therapy – our drug-nebulizer expertise

All you need to know about our partnering approach for pharmaceutical companies.


Read more

Developing new drug-nebulizer combination products

Developing new drug-nebulizer combination products

Are you interested in the critical success factors and opportunities for bringing a new vibrating membrane nebulizer for a drug-device combination product to the market?

Read more

Contact us

Do you have any questions about our technology, partnering approach and services?

Please contact us!


I have acknowledged the information regarding data processing.